Cost and Coverage in Genomic Testing Medicine - Economic Perspectives

Explore the economic perspectives of cost and coverage in genomic testing medicine through this informative webinar. Delve into terms and analytical methods used for evaluating healthcare interventions economically, and understand how US public and private payers consider cost and effectiveness information when making value-based coverage and reimbursement decisions. Learn about the implications for adopting new genomic technologies in clinical practice. Gain insights from Scott Grosse, PhD, a senior health economist at the CDC, as he shares his expertise on rare disorders, neurodevelopmental disorders, and public health strategies. Discover various economic evaluation methods, including cost-effectiveness analysis and budgetary impact analysis. Understand the concept of QALYs and how to assess cost-effectiveness or cost savings by comparing different strategies. Examine Medicare coverage of genomic tests and counseling, particularly for hereditary cancers. Investigate the cost-effectiveness of genetic testing for hereditary cancers, including tumor testing for Lynch syndrome in newly diagnosed colorectal cancer patients.

Intro
Which outcomes or types of evidence matter? May vary by stakeholder type
Economic evaluation methods . Cost-effectiveness analysis (CEA)
Which economic evaluation method to use? • Payers may prefer budgetary impact analysis
What is a QALY? . Summary measure of population health
Cost-effectiveness . How to assess cost-effectiveness or cost savings - Comparison of two strategies
Modeling uncertainty in parameters • One-way sensitivity analyses - Parameters have specified range and distribution of estimates - Model is run using extreme estimates for each parameter leaving all
Medicare coverage of genomic tests and counseling . Genetic testing and counseling can be paid by Medicare for persons with certain diseases, based on medical necessity
Medicare and genetic testing for hereditary cancers: hereditary breast and ovarian cancer
Is genetic testing for hereditary cancers cost-effective? • Tumor testing for Lynch syndrome - In newly diagnosed patients with colorectal cancer (CRC) followed by